title: Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.
abstract: In previous clinical trials, recombinant interleukin-2 (rIL-2) has been infused at high doses over short periods of time to generate lymphokine-activated killer (LAK) cells in vivo. These trials have been limited by severe toxicities, and the immunologic effects of rIL-2 have been transient. The present study was designed to assess the toxicity and immunologic effects of prolonged administration of low doses of rIL-2. In this phase I study, patients with advanced cancer were scheduled to receive intravenous (IV) infusion of rIL-2 without interruption for 3 months in an outpatient setting. Twenty-one patients received rIL-2 at doses ranging from 0.5 x 10(5) to 6.0 x 10(5) U/m2/d. Treatment was extremely well tolerated, and no patient experienced grade 3 or grade 4 toxicity. The lowest dose level (0.5 x 10(5) U/m2/d) did not have demonstrable immunologic activity. At doses of 1.5 x 10(5) and 4.5 x 10(5) U/m2/d, rIL-2 infusion resulted in the specific expansion of natural-killer (NK) cells (sixfold and ninefold increases, respectively, at these two dose levels) without any changes in B cells, T cells, neutrophils, or monocytes. Grade 2 toxicity was observed at the dose of 6.0 x 10(5) U/m2/d, as three patients required interruption of therapy and two patients who completed therapy developed transient hypothyroidism. In patients with increased NK cells, enhancement of non-major histocompatibility complex (MHC)-restricted cytotoxicity and increased generation of LAK cells in vitro were also demonstrated. Therapy with low-dose rIL-2 can be given safely in an uninterrupted fashion for prolonged periods of time in an outpatient setting. This results in selective expansion of NK cells in vivo with minimal toxicity. Further investigation of this schedule for immunomodulation in vivo should be pursued in phase II studies of both malignant and immunodeficient disease states.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA 02115.
authors.forename: M A
authors.initials: MA
authors.lastname: Caligiuri
authors.forename: C
authors.initials: C
authors.lastname: Murray
authors.forename: R J
authors.initials: RJ
authors.lastname: Soiffer
authors.forename: T R
authors.initials: TR
authors.lastname: Klumpp
authors.forename: M
authors.initials: M
authors.lastname: Seiden
authors.forename: K
authors.initials: K
authors.lastname: Cochran
authors.forename: C
authors.initials: C
authors.lastname: Cameron
authors.forename: C
authors.initials: C
authors.lastname: Ish
authors.forename: L
authors.initials: L
authors.lastname: Buchanan
authors.forename: D
authors.initials: D
authors.lastname: Perillo
mesh_terms: D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D002405:Catheterization, Central Venous; D002408:Catheters, Indwelling; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects*; D008218:Lymphocytosis / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins